This is what people need to realize, and that is Zalicus is generating revenue. I find this to be one of the most important dynamics going forward. Below is a piece of this mornings new article.
"Not many biotechs trading under $3 generate any revenues. If Z160 is successful in clinical trials and matches gabapentin, or lyrica sales, it would easily justify a stock price over 20 times the current price. Analysts have estimated the market opportunity for Z160 to be anywhere from $500 million to $2.7 billion. Comparable to peak sales for gabapentin. Z160 could see significant off label usage being that it is a non-opioid with a superior side effect profile. The FDA has made a significant effort to approve drugs with less abuse potential which favors non-opioids such as Z160."